• Male or female, aged ≥18 years at the time of signing informed consent

• Upon central biopsy reading process: diagnosis of NASH according to the Steatosis-Activity-Fibrosis (SAF):

‣ Steatosis score ≥1

⁃ Activity score: A3 or A4

⁃ Fibrosis score: F2 or F3

• No qualitative change in dose for the drugs listed below:

‣ Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months

⁃ Vitamin E (if at a dose ≥400 IU/day): for at least 6 months

⁃ Statins: for at least 3 months

• No qualitative change in dose for all other chronically administered drugs for at least 3 months prior to Screening

• Weight stable for 6 months prior to Screening and between the qualifying liver biopsy and Baseline (no more than 5% change for both periods)

• Negative serum pregnancy test at study Screening for females of childbearing potential confirmed by central laboratory. Females of childbearing potential must practice a consistent and proper use of highly effective method of contraception throughout the study and for 1 month after treatment discontinuation.